Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.37 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21649342 | 0.89 | TP53 (0.38) | KDM4EHSD17B10GAAMAP3K5 | |
| SCHEMBL21649344 | 0.82 | MAP3K5 (0.49) | MAP3K5 | |
| SCHEMBL28368603 | 0.70 | RAB9A (0.40) | KDM4EGABRA2GABRB2GABRG2GABRB3 | |
| SCHEMBL28657005 | 0.70 | ALDH1A1 (0.41) | KDM4EHSD17B10GAAMAP3K5 | |
| SCHEMBL30998146 | 0.69 | CYP4F2 (0.50) | BAZ2BBAZ2AJMJD6CA12CA1 | |
| SCHEMBL5280799 | 0.68 | CYP4F2 (0.49) | BAZ2BBAZ2AJMJD6GAACA12 | |
| SCHEMBL17880577 | 0.67 | MAP3K5 (0.55) | MAP3K5 | |
| SCHEMBL28643394 | 0.66 | ALDH1A1 (0.41) | KDM4EHSD17B10MAP3K5 | |
| SCHEMBL365356 | 0.66 | CYP4F2 (0.49) | BAZ2BBAZ2AJMJD6CA12CA1 | |
| SCHEMBL28614404 | 0.66 | PDE4D (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | Fuijan Cosunter Pharmaceutical Co. Ltd. (CN) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | MARK1, MAP3K1, MAP3K20 | KDM4E 2985/4885HSD17B10 1964/4885GABRA2 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.